Page last updated: 2024-11-05

nitroxoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nitroxoline is an antibacterial drug that was originally synthesized in the 1950s. It is effective against a variety of bacterial infections, including urinary tract infections, skin infections, and gastrointestinal infections. Nitroxoline is thought to work by interfering with the synthesis of bacterial DNA. It is available in a variety of oral and topical formulations. Nitroxoline has been studied extensively for its potential as a treatment for urinary tract infections. It is effective in treating both uncomplicated and complicated urinary tract infections. However, nitroxoline is not as widely used as other antibacterial drugs, such as ciprofloxacin and trimethoprim-sulfamethoxazole. This is due to the fact that nitroxoline can cause side effects, such as nausea, vomiting, and diarrhea. Nitroxoline is also used to treat other infections, such as skin infections and gastrointestinal infections. However, its use in these infections is less common than in urinary tract infections.'

nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID19910
CHEMBL ID1454910
CHEBI ID67121
SCHEMBL ID151248
MeSH IDM0046773

Synonyms (105)

Synonym
brn 0166146
einecs 223-662-4
nicene forte
nitroxolina [inn-spanish]
bas 58
isinok
uro-coli
nsc 74947
galinok
nitroxoline [inn:ban:dcf]
nitroxolinum [inn-latin]
MLS001148594
MLS000069750 ,
smr000059036
D07245
nitroxoline (inn)
nitroxoline (tn)
5-nitro-8-quinolinol
5-nitro-8-oxyquinoline
nitroxoline
wln: t66 bnj gnw jq
8-hydroxy-5-nitroquinoline
noxibiol
5-nitro-8-oxychinoline
noxin
nsc74947
nibiol
5-nok
nitroxolin
a-82
nsc-74947
5-nitroks
5-nitroxine
5nok
5-nitro-8-hydroxyquinoline
OPREA1_594857
STK099582
8-quinolinol, 5-nitro-
4008-48-4
5-nitroquinolin-8-ol ,
inchi=1/c9h6n2o3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12
DB01422
5-nitrox
NCGC00160664-01
8-hydroxy-5-nitroquinoline, 96%
AC-7828
H0805
KUC105356N
ksc-8-140
AKOS001053242
CHEMBL1454910
chebi:67121 ,
nitrohydroxyquinoline
A6696
HMS3264C05
hnq ,
dtxsid4046284 ,
dtxcid2026284
tox21_111969
cas-4008-48-4
nsc760393
nsc-760393
pharmakon1600-01506173
nitroxolinum
nitroxolina
HMS2230I14
S4591
5-21-03-00297 (beilstein handbook reference)
unii-a8m33244m6
a8m33244m6 ,
FT-0621541
PS-5547
REGID_FOR_CID_19910
AG-205/04556035
HMS3374D08
nitroxoline [inn]
nitroxoline [mi]
nitroxoline [who-dd]
nitroxoline [mart.]
CCG-213981
SCHEMBL151248
tox21_111969_1
NCGC00160664-03
3AI8
5-nitro-8hydroxyquinoline
CS-4761
W-106391
cid_19910
bdbm64987
HY-B1159
5-nitro-quinolin-8-ol
quinolin-8-ol, 5-nitro-
AB00572598_14
OPERA_ID_204
mfcd00006791
5-nitroquinolin-8-ol, 96%
SR-01000721863-4
sr-01000721863
Z56922155
Q304570
5-nitro-8-quinolinol|5-nitro-8-hydroxyquinoline
8-hydroxy-5-nitro-chinoline
AMY23308
EN300-17364
nitroxlina

Research Excerpts

Overview

Nitroxoline was identified in a screen for drugs with amebicidal activity against Balamuthia. Nitroxoline is an antibiotic by chelating Zn2+ and Fe2+ from biofilm matrix.

ExcerptReferenceRelevance
"Nitroxoline is a broad-spectrum antibiotic with restricted indication for urinary tract infections."( Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
Brunst, S; Burgers, LD; Frank, D; Fürst, R; Gobec, S; Martinelli, G; Proschak, A; Proschak, E; Rotter, MJ; Sosič, I; Weizel, L; Wichelhaus, TA, 2022
)
2.89
"Nitroxoline, which is a quinolone typically used to treat urinary tract infections, was identified in a screen for drugs with amebicidal activity against Balamuthia."( Successful Treatment of Balamuthia mandrillaris Granulomatous Amebic Encephalitis with Nitroxoline.
Bollen, A; Boutros, CL; Chiu, CY; DeRisi, JL; Fouassier, C; Gruenberg, K; Kim, A; Laurie, MT; Lu, R; Pet, D; Ramachandran, A; Servellita, V; Shah, M; Spottiswoode, N; Valdivia, L; Wilson, MR; Zhang, Y; Zia, M, 2023
)
1.85
"Nitroxoline is an antibiotic with metal-chelating activity used to treat urinary tract infections."( Rationally repurposed nitroxoline inhibits preclinical models of Epstein-Barr virus-associated lymphoproliferation.
Damoci, CB; Ibáñez de Garayo, M; Liu, W; Miranda, JJL; Rondeau, NC, 2021
)
1.66
"Nitroxoline is an old antibiotic, which has recently been re-launched for the treatment of uncomplicated urinary tract infection."( Susceptibility of carbapenemase-producing Enterobacterales (CPE) to nitroxoline.
Fuchs, F; Hamprecht, A, 2019
)
1.47
"Nitroxoline is an FDA-approved antibiotic with potential antitumor activity. "( Nitroxoline induces apoptosis and slows glioma growth in vivo.
Ellingson, B; Guo, L; Kim, HJ; Lazovic, J; Mirsadraei, L; Nakashima, J; Pope, WB; Wu, H; Yong, W, 2015
)
3.3
"Nitroxoline is an antibiotic by chelating Zn2+ and Fe2+ from biofilm matrix. "( Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
Chang, WL; Chen, CS; Guh, JH; Hsu, LC; Leu, WJ, 2015
)
2.21
"Nitroxoline is an oxyquinoline derivative with a large antifungical activity. "( [In vitro antifungal activity of nitroxoline. Preliminary clinical results].
Amgar, A; Cancet, B, 1987
)
2

Effects

Nitroxoline has been found to have effective anticancer properties in several cancer types. It has been reduced at the mercury electrode in buffered solutions (pH 2-11) in two irreversible cathodic steps.

ExcerptReferenceRelevance
"Nitroxoline has a promising in vitro activity against drug-resistant MYABS isolates. "( Activity of the old antimicrobial nitroxoline against Mycobacterium abscessus complex isolates.
Fuchs, F; Hoffmann, AM; Plum, G; Rybniker, J; Wolke, M, 2023
)
2.63
"Nitroxoline has a promising in vitro activity against drug-resistant MYABS isolates. "( Activity of the old antimicrobial nitroxoline against Mycobacterium abscessus complex isolates.
Fuchs, F; Hoffmann, AM; Plum, G; Rybniker, J; Wolke, M, 2023
)
2.63
"Nitroxoline has excellent in vitro activity against C. auris isolates, with MICs of 0.125-1 mg/L (for comparison, the EUCAST breakpoint for uncomplicated urinary tract infection with Escherichia coli is ≤ 16 mg/L). "( Antifungal activity of nitroxoline against Candida auris isolates.
Fuchs, F; Hamprecht, A; Hof, H; Hofmann, S; Kurzai, O; Meis, JF, 2021
)
2.37
"Nitroxoline has been found to have effective anticancer properties in several cancer types."( The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer.
Araki, M; Huang, L; Huang, P; Li, C; Li, Q; Li, X; Liu, C; Nasu, Y; Wada, K; Watanabe, M; Xu, A; Xu, N, 2019
)
1.54
"Nitroxoline has been reduced at the mercury electrode in buffered solutions (pH 2-11) in two irreversible cathodic steps. "( Electrochemistry of the antibacterial and antifungal drug nitroxoline and its determination in bulk form, pharmaceutical formulation and human blood.
Abdel-Galeil, MM; El-Desoky, HS; Ghoneim, MM, 2011
)
2.06

Pharmacokinetics

ExcerptReferenceRelevance
"The authors carried out initial pharmacokinetic studies of 5-nitrox on patients with compensated, first and second degree of decompensated renal insufficiency in view of determining dosage and intervals for application of the preparation."( [Pharmacokinetic studies of 5-nitrox in kidney failure patients].
Dzhoneĭdi, M; Mikhaĭlova, D; Mikhaĭlova, S; Tsenova, Z; Viktorov, I, 1981
)
0.26

Compound-Compound Interactions

ExcerptReferenceRelevance
" The LoC-SERS technique combined with the standard addition method and statistical data analysis provided a good prediction of the unknown concentrations."( Lab-on-a-Chip-Surface Enhanced Raman Scattering Combined with the Standard Addition Method: Toward the Quantification of Nitroxoline in Spiked Human Urine Samples.
Bocklitz, T; Cialla-May, D; Hidi, IJ; Jahn, M; Pletz, MW; Popp, J; Weber, K, 2016
)
0.64

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Clinical studies in relevant patient populations are needed with commercially available nitrofurantoin and nitroxoline formulations at approved dosing regimens to more fully characterize their PK profiles. The study was carried out by urologists, general practitioners (GPs), and internists in family medicine throughout Germany.

ExcerptRelevanceReference
"The authors carried out initial pharmacokinetic studies of 5-nitrox on patients with compensated, first and second degree of decompensated renal insufficiency in view of determining dosage and intervals for application of the preparation."( [Pharmacokinetic studies of 5-nitrox in kidney failure patients].
Dzhoneĭdi, M; Mikhaĭlova, D; Mikhaĭlova, S; Tsenova, Z; Viktorov, I, 1981
)
0.26
" Clinical studies in relevant patient populations are needed with commercially available nitrofurantoin and nitroxoline formulations at approved dosing regimens to more fully characterize their PK profiles, and to investigate the influence of patient characteristics on these profiles in order to optimize efficacy and avoid toxicity and emergence of resistance."( Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline.
Huttner, A; Koch, BCP; Mouton, JW; Muller, AE; Wijma, RA, 2018
)
0.93
"Female patients with UC treated with nitroxoline (recommended dosage 250 mg tid for 5 days) were included by urologists, general practitioners (GPs), and internists in family medicine throughout Germany from April-December 2022 and followed for 21-28 days."( [Therapy of cystitis with nitroxoline-NitroxWin : Prospective, multicenter, non-interventional study and microbiological resistance surveillance].
Bahrs, C; Grabein, B; Kresken, M; Naber, KG; Strohmaier, WL; Wagenlehner, F; Wohlfarth, E, 2023
)
1.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
renal agentA drug used for its effect on the kidneys' regulation of body fluid composition and volume.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
monohydroxyquinolineA hydroxyquinoline carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (104)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.39810.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency39.81070.044717.8581100.0000AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency22.38720.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency2.81840.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency75.11370.100020.879379.4328AID588453; AID588456
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.47723.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.67360.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency19.22380.004110.890331.5287AID504466; AID504467
Fumarate hydrataseHomo sapiens (human)Potency6.30960.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency53.80830.031637.5844354.8130AID504865; AID743255
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency3.71710.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.35600.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency8.91250.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency10.20400.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency3.98110.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency5.95570.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.86060.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency0.53080.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.12200.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency23.91450.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency20.68950.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency2.39400.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.59450.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency8.41200.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency21.98730.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.62730.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
polyproteinZika virusPotency6.30960.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency9.45630.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency3.54810.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency10.59010.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency15.08900.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency8.35830.023723.228263.5986AID743222; AID743223; AID743241
IDH1Homo sapiens (human)Potency6.51310.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency20.40530.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency4.18010.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency7.49780.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.239119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency7.00880.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency28.97100.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency5.95570.006723.496068.5896AID1346980
beta-2 adrenergic receptorHomo sapiens (human)Potency2.81840.00586.026332.6427AID492947
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency6.30960.01262.451825.0177AID485313
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency31.62281.000012.232631.6228AID1452
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency3.66260.00419.984825.9290AID504444
caspase-3Cricetulus griseus (Chinese hamster)Potency5.95570.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency4.24430.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency0.15080.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency9.82780.000618.41981,122.0200AID1688; AID2669; AID2673
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
flap endonuclease 1Homo sapiens (human)Potency2.81840.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency6.30960.00022.621531.4954AID485297
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency1.33320.000627.21521,122.0200AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.49970.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency9.28190.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency17.76930.005612.367736.1254AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency28.18380.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency22.38720.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency0.89130.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency18.83360.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency29.41070.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency6.68240.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency18.83360.001551.739315,848.9004AID1259244
Alpha-synucleinHomo sapiens (human)Potency15.84890.56239.398525.1189AID652106
TAR DNA-binding protein 43Homo sapiens (human)Potency7.94331.778316.208135.4813AID652104
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency4.21630.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency4.21630.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, Cathepsin BHomo sapiens (human)Ki154.4000154.4000154.4000154.4000AID977610
nonstructural protein 1Influenza A virus (A/California/07/2009(H1N1))IC50 (µMol)4.72300.200024.4540100.0000AID504329
photoreceptor-specific nuclear receptorHomo sapiens (human)IC50 (µMol)8.96200.03742.93408.9620AID624394
transactivating tegument protein VP16 [Human herpesvirus 1]Human alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)6.35700.94604.70169.4870AID624395
VifHuman immunodeficiency virus 1IC50 (µMol)46.53000.270034.0015100.0000AID1117319
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)46.53000.270026.3638100.0000AID1117319
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)0.98000.00040.40329.0500AID1534670; AID1534671
Cathepsin BHomo sapiens (human)Ki155.23330.00001.21808.6000AID1390111; AID1390112; AID1390118; AID723760; AID723761; AID723762
Catechol O-methyltransferaseRattus norvegicus (Norway rat)IC50 (µMol)19.95260.00222.81277.0795AID1149251
Cystathionine gamma-lyaseHomo sapiens (human)IC50 (µMol)8.23330.57002.86098.0000AID1680645; AID1680647; AID1680654
Mu-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)6.00000.00010.887410.0000AID1680647
Prostaglandin G/H synthase 2Homo sapiens (human)Ki1.00000.00050.41861.5000AID1053267
Methionine aminopeptidase 2Homo sapiens (human)IC50 (µMol)0.05500.00060.96835.6000AID1598080; AID760045
Methionine aminopeptidase 1Homo sapiens (human)IC50 (µMol)15.00008.10008.10008.1000AID760046
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
citrate synthase 2, partialSaccharomyces cerevisiae (brewer's yeast)EC50 (µMol)14,600.00001.07003.07785.7170AID488827
heat shock protein 90Candida albicansEC50 (µMol)0.68100.12006.485533.8530AID2423
LAP4Saccharomyces cerevisiae (brewer's yeast)EC50 (µMol)2.64300.45008.371433.0000AID2745; AID488795
RPL19ASaccharomyces cerevisiae (brewer's yeast)EC50 (µMol)25.36000.42005.576025.3600AID488808
amino acid transporter AGP1Saccharomyces cerevisiae S288CEC50 (µMol)5.98000.78105.853710.8000AID488792
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)19.71500.018023.2882287.6000AID434968; AID435010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MSHDrosophila melanogaster (fruit fly)AC5048.69000.20909.578848.6900AID743444
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC5014.86000.063611.235844.9700AID720632
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC500.99600.19503.667918.6960AID540270
replicative DNA helicaseMycobacterium tuberculosis H37RvAC508.27750.057030.7482325.3000AID449749; AID449750
heat shock protein 90, putativePlasmodium falciparum 3D7AC501.65700.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (339)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
cysteine metabolic processCystathionine gamma-lyaseHomo sapiens (human)
lipid metabolic processCystathionine gamma-lyaseHomo sapiens (human)
protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic process via cystathionineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
transsulfurationCystathionine gamma-lyaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCystathionine gamma-lyaseHomo sapiens (human)
protein sulfhydrationCystathionine gamma-lyaseHomo sapiens (human)
protein homotetramerizationCystathionine gamma-lyaseHomo sapiens (human)
hydrogen sulfide biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of aortic smooth muscle cell differentiationCystathionine gamma-lyaseHomo sapiens (human)
cellular response to leukemia inhibitory factorCystathionine gamma-lyaseHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCystathionine gamma-lyaseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
protein processingMethionine aminopeptidase 2Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 2Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 2Homo sapiens (human)
regulation of translationMethionine aminopeptidase 1Homo sapiens (human)
proteolysisMethionine aminopeptidase 1Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 1Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 1Homo sapiens (human)
protein maturationMethionine aminopeptidase 1Homo sapiens (human)
platelet aggregationMethionine aminopeptidase 1Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (97)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
cystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
protein bindingCystathionine gamma-lyaseHomo sapiens (human)
calmodulin bindingCystathionine gamma-lyaseHomo sapiens (human)
pyridoxal phosphate bindingCystathionine gamma-lyaseHomo sapiens (human)
identical protein bindingCystathionine gamma-lyaseHomo sapiens (human)
L-cystine L-cysteine-lyase (deaminating)Cystathionine gamma-lyaseHomo sapiens (human)
homocysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
L-cysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
selenocystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA bindingMethionine aminopeptidase 2Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
protein bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
protein bindingMethionine aminopeptidase 1Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 1Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (61)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolCystathionine gamma-lyaseHomo sapiens (human)
extracellular exosomeCystathionine gamma-lyaseHomo sapiens (human)
cytoplasmCystathionine gamma-lyaseHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
cytosolMethionine aminopeptidase 2Homo sapiens (human)
plasma membraneMethionine aminopeptidase 2Homo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
cytoplasmMethionine aminopeptidase 1Homo sapiens (human)
cytosolMethionine aminopeptidase 1Homo sapiens (human)
cytosolic ribosomeMethionine aminopeptidase 1Homo sapiens (human)
cytosolMethionine aminopeptidase 1Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (157)

Assay IDTitleYearJournalArticle
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745846Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID723762Mixed inhibition of cathepsin B (unknown origin) endopeptidase activity assessed as inhibition constant for enzyme-inhibitor complex2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID1440391Antibiofilm activity against fluconazole-resistant Candida albicans 29E clinical isolates after 48 hrs by Alamar blue assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID1862446Antibiofilm activity against methicillin-resistant Staphylococcus aureus USA 300 in TSB broth assessed as dispersal of glucose-induced biofilm preincubated with glucose for 48 hrs followed by compound addition and measured after 24 hrs by crystal violet s2022European journal of medicinal chemistry, Oct-05, Volume: 240Membrane acting Povarov-Doebner derived compounds potently disperse preformed multidrug resistant Gram-positive bacterial biofilms.
AID1680651Binding affinity to H2S assessed as absorbing of released H2S at 200 uM in presence of NaHS as H2S donor2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1680653Selectivity index, ratio of IC50 for human CBS to IC50 for human DDC2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1680647Inhibition of human CSE using H-Cys as the substrate by LC/MS/MS-based assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID723757Inhibition of human recombinant cathepsin B endopeptidase activity using Z-Arg-Arg-AMC substrate at 50 uM2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID760039Antibacterial activity against Burkholderia pseudomallei Bp340 assessed as bacterial growth inhibition at 31.25 uM after 24 hrs by two-fold dilution method2013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1862453Antibiofilm activity against vancomycin-resistant Enterococcus faecalis ATCC 51575 in TSB broth assessed as dispersal of glucose-induced biofilm preincubated with glucose for 48 hrs followed by compound addition and measured after 24 hrs by crystal violet2022European journal of medicinal chemistry, Oct-05, Volume: 240Membrane acting Povarov-Doebner derived compounds potently disperse preformed multidrug resistant Gram-positive bacterial biofilms.
AID1390118Non-competitive inhibition of recombinant human cathepsin B exopeptidase activity assessed as inhibitory constant for enzyme-inhibitor complex using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH as substrate in presence of pH 5 acetate buffer by fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Cathepsin B inhibitors: Further exploration of the nitroxoline core.
AID1882264Induction of mitotic arrest in human multiple myeloma cells2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1339164Cytotoxicity against CD rat primary pulmonary vascular endothelial cells assessed as reduction in cell viability at 0.003 to 3 uM measured after 72 hrs by WST1 assay2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID1598080Inhibition of recombinant human N-terminal His-tagged MetAP2 expressed in baculovirus infected BTI-TN-5B1-4 insect cells using Met-Pro-pNA as substrate preincubated for 20 mins followed by substrate addition and measured after 30 mins2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.
AID1053269Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID723750Selectivity ratio of Ki for human liver cathepsin H to Ki for human recombinant cathepsin B2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID1390112Mixed inhibition of recombinant human cathepsin B endopeptidase activity assessed as inhibitory constant for enzyme-substrate-inhibitor complex using Z-Arg-Arg-AMC as substrate in presence of pH 6 phosphate buffer by fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Cathepsin B inhibitors: Further exploration of the nitroxoline core.
AID1681660Antibacterial activity against Enterococcus faecium ATCC 19434 assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID1534670Inhibition of BRD4 in human MV4-11 cells using biotin labelled N-C:SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by alpha screen assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
AID1053267Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID760044Antibacterial activity against Burkholderia thailandensis E264 assessed as bacterial growth inhibition after 24 hrs by two-fold dilution method2013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID723756Inhibition of human recombinant cathepsin B exopeptidase activity using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH substrate at 50 uM2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID1862417Antibiofilm activity against vancomycin-resistant Enterococcus faecium ATCC 700221 in TSB broth assessed as dispersal of glucose-induced biofilm preincubated with glucose for 48 hrs followed by compound addition and measured after 24 hrs by crystal violet2022European journal of medicinal chemistry, Oct-05, Volume: 240Membrane acting Povarov-Doebner derived compounds potently disperse preformed multidrug resistant Gram-positive bacterial biofilms.
AID1824260Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1053268Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1824265Inhibition of recombinant VIM-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1598078Antiproliferative activity against HUVEC measured after 24 hrs by [3H]-thymidine incorporation assay2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.
AID1339155Inhibition of Rickettsia prowazekii str. Madrid E N-terminal His-tagged methionine aminopeptidase 1A expressed in Escherichia coli BL21(DE3) Rosetta cells using Met-AMC as substrate preincubated for 1 hr followed by substrate addition measured after 30 mi2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID1681662Antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID1681661Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID1824263Inhibition of recombinant VIM-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID11369641-Octanol-water partition coefficient, log P of the compound by spectrophotometer analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID1390120Inhibition of recombinant human cathepsin B endopeptidase activity assessed as residual activity at 50 uM using Z-Arg-Arg-AMC as substrate in presence of pH 6 phosphate buffer by fluorescence assay relative to control2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Cathepsin B inhibitors: Further exploration of the nitroxoline core.
AID723751Selectivity ratio of Ki for human recombinant cathepsin L to Ki for human recombinant cathepsin B2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID1680645Inhibition of human CSE using H-Cys as the substrate by tandem well based HTS assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1390111Mixed inhibition of recombinant human cathepsin B endopeptidase activity assessed as inhibitory constant for enzyme-inhibitor complex using Z-Arg-Arg-AMC as substrate in presence of pH 6 phosphate buffer by fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Cathepsin B inhibitors: Further exploration of the nitroxoline core.
AID723760Noncompetitive inhibition of cathepsin B (unknown origin) exopeptidase activity assessed as inhibition constant for enzyme-inhibitor complex2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID1534674Stabilization of BRD4 BD1 (unknown origin) assessed as change in melting temperature at protein to test compound molar ratio of 1:40 by SYPRO Orange dye based fluorescence analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
AID1824262Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1681663Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID1681664Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID1149251Inhibition of Sprague-Dawley rat liver COMT after 10 mins using 0.05 uCi [14CH3]-SAM as substrate1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Catechol O-methyltransferase. 8. Structure-activity relationships for inhibtion by 8-hydroxyquinolines.
AID760038Antibacterial activity against Burkholderia pseudomallei 1026b assessed as bacterial growth inhibition after 24 hrs by two-fold dilution method2013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1824268Inhibition of recombinant IMP-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1136966Ionization constant, pKa of quinoline nitrogen group of the compound at 1 mM by potentiometric analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID760046Inhibition of human methionine aminopeptidase 12013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1136967Ionization constant, pKa of substituent at 5th position of the compound at 1 mM by potentiometric analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID1136965Ionization constant, pKa of 8-hydroxyl group of the compound at 1 mM by potentiometric analysis1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID11369691-Octanol-water partition coefficient, log P of the compound by spectrophotometer analysis corrected for ionization1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque.
AID760041Bactericidal activity against Burkholderia thailandensis E264 assessed as cell death after 24 hrs by two-fold dilution method2013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1534671Inhibition of BRD4 BD1 (unknown origin) using biotin labelled NeC: SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by alpha screen assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
AID1680650Binding affinity to H2S assessed as absorbing of released H2S up to 100 uM in presence of NaHS as H2S donor2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1339160Antibacterial activity against Rickettsia prowazekii str. Breinl infected in CD rat primary pulmonary vascular endothelial cells assessed as protection against bacterial infection by measuring restoration of host cell viability at 0.003 to 3 uM measured 72017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
AID723761Mixed inhibition of cathepsin B (unknown origin) endopeptidase activity assessed as inhibition constant for enzyme-substrate-inhibitor complex2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
AID1824266Inhibition of recombinant IMP-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1824261Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1680649Inhibition of human CSE using L-Cys as the substrate in presence of 0.025% Triton X-100 by tandem well based HTS assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1824264Inhibition of recombinant VIM-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1534675Antiproliferative activity against human MV4-11 cells after 72 hrs by CellTiter Glo luminescent assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
AID1681665Antibacterial activity against Enterobacter cloacae ATCC 13047 assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID760043Antibacterial activity against Burkholderia thailandensis E264 assessed as bacterial growth inhibition at 1 mM after 24 hrs by two-fold dilution method relative to DMSO-treated control2013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1824267Inhibition of recombinant IMP-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1824329Cytotoxicity against human HUVEC cells assessed as metabolic activity measured after 24 hrs by cell-titer blue assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1681666Antibacterial activity against Escherichia coli assessed as reduction in bacterial growth by serial dilution method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.
AID760045Inhibition of human methionine aminopeptidase 22013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1390121Inhibition of recombinant human cathepsin B exopeptidase activity assessed as residual activity at 50 uM using Abz-Gly-Ile-Val-Arg-Ala-Lys(Dnp)-OH as substrate in presence of pH 5 acetate buffer by fluorescence assay relative to control2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Cathepsin B inhibitors: Further exploration of the nitroxoline core.
AID1440390Antibiofilm activity against Candida albicans SC5314 after 48 hrs by Alamar blue assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID1440392Antibiofilm activity against Candida albicans SC5314 after 24 hrs by Cell-Titer Blue assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID1680654Inhibition of human CSE using L-Cys as the substrate by tandem well based HTS assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1440389Antibiofilm activity against Candida albicans CAF2-1 after 48 hrs by Alamar blue assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID760047Inhibition of Burkholderia pseudomallei recombinant methionine aminopeptidase 1 using H-Met-Gly-Pro-7-amino-4-methylcoumarin hydrochloride as substrate measured for 10 mins by fluorescence assay in presence of human recombinant DPP42013ACS medicinal chemistry letters, Jul-01, Volume: 4, Issue:8
Discovery of Inhibitors of
AID1680648Inhibition of human CSE using L-Cys as the substrate in presence of 0.01% Triton X-100 by tandem well based HTS assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID1680652Selectivity index, ratio of IC50 for human CBS to IC50 for human CSE2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2011ChemMedChem, Aug-01, Volume: 6, Issue:8
Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (133)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (22.56)18.7374
1990's4 (3.01)18.2507
2000's5 (3.76)29.6817
2010's60 (45.11)24.3611
2020's34 (25.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.51 (24.57)
Research Supply Index5.00 (2.92)
Research Growth Index5.56 (4.65)
Search Engine Demand Index84.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (4.23%)5.53%
Reviews8 (5.63%)6.00%
Case Studies4 (2.82%)4.05%
Observational0 (0.00%)0.25%
Other124 (87.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]